Lyell Immunopharma (LYEL) Net Margin: 2020-2025
Historic Net Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -226,580.00%.
- Lyell Immunopharma's Net Margin fell 9558000.00% to -226,580.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -798,982.93%, marking a year-over-year decrease of 49599245.00%. This contributed to the annual value of -548,667.21% for FY2024, which is 37670183.00% down from last year.
- Lyell Immunopharma's Net Margin amounted to -226,580.00% in Q3 2025, which was up 58.68% from -548,300.00% recorded in Q2 2025.
- Lyell Immunopharma's 5-year Net Margin high stood at -23.42% for Q4 2022, and its period low was -2,139,533.33% during Q3 2022.
- In the last 3 years, Lyell Immunopharma's Net Margin had a median value of -347,415.38% in 2024 and averaged -577,603.43%.
- As far as peak fluctuations go, Lyell Immunopharma's Net Margin crashed by 213,775,871bps in 2022, and later skyrocketed by 192,980,933bps in 2023.
- Over the past 5 years, Lyell Immunopharma's Net Margin (Quarterly) stood at -1,673.10% in 2021, then surged by 164,969bps to -23.42% in 2022, then tumbled by 40,323,812bps to -403,261.54% in 2023, then crashed by 138,062,028bps to -1,783,881.82% in 2024, then tumbled by 9,558,000bps to -226,580.00% in 2025.
- Its last three reported values are -226,580.00% in Q3 2025, -548,300.00% for Q2 2025, and -764,357.14% during Q1 2025.